U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H28NO3
Molecular Weight 342.4519
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of METHYLBENACTYZIUM

SMILES

CC[N+](C)(CC)CCOC(=O)C(O)(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=HDAMOICMOAXFLJ-UHFFFAOYSA-N
InChI=1S/C21H28NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,24H,4-5,16-17H2,1-3H3/q+1

HIDE SMILES / InChI

Description

Methylbenactyzium bromide has been used as a spasmolytic for the treatment of gastrointestinal ulcer and gastrointestinal spasms.

CNS Activity

CNS Active
3,913

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
Muscarinic acetylcholine receptor M4
86
Antagonist
2,778
 13.2 nM [Ki]
Muscarinic acetylcholine receptor M2
121
Antagonist
2,778
 1.54 nM [Ki]
Muscarinic acetylcholine receptor M3
159
Antagonist
2,778
 4.25 nM [Ki]
Muscarinic acetylcholine receptor M1
169
Antagonist
2,778
 1.59 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Gastrointestinal spasm
2
 Primary
Approved
8,429
Finalin

PubMed

Patents

EP1364659B1
2
US20040086536
2
US20070116729
21
US5985843
2
US7288558
2

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
Unknown
SALT/SOLVATE (PARENT)
Structure of METHYLBENACTYZIUM BROMIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966